NCT04856137View on ClinicalTrials.gov

A Phase I/II Study of Diffuse Large B-cell Lymphoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2028

Conditions
Refractory Diffuse Large B-cell Lymphoma
Interventions
DRUG

Rituximab Paclitaxel Ruxolitinib

Rituximab 375mg/m2 on D1 of each cycle Paclitaxel 200mg/m2 on D1 of each cycle Ruxolitinib continuously given (D1-21)

All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

China Medical University Hospital

OTHER

collaborator

Shin Kong Wu Huo-Shih Memorial Hospital

UNKNOWN

lead

National Health Research Institutes, Taiwan

OTHER